Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Aidea Pharmaceutical Co., Ltd. (688488.SS)
Yangzhou, CN
Jiangsu Aidea Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and commercialization of diverse pharmaceutical products. Its extensive offerings encompass a range of medications including folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules. The company also provides pharmaceutical raw materials. Established in 2009, Jiangsu Aidea Pharmaceutical is headquartered in Yangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.11% | -0.51% | -10.08% | -4.84% | +15.65% | -4.96% | +12.06% | +20.12% | -25.60% | -49.81% | -49.81% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+72.5% ★ Q1'26: -10.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+85.3% ★ Q1'26: -54.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-10.8% Q1'26: -3.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+3.4% ★ Q1'26: +10.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.4% ★ Q1'26: +5.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-6.2% ★ Q1'26: +8.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×6.14× ★ Q1'26: 9.68× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
244.22M
est: 244.00M (+0.1%)
|
411.36M
est: 417.00M (-1.4%)
|
417.80M
est: 439.00M (-4.8%)
|
720.67M
est: 755.00M (-4.5%)
|
1.01B
1.01B – 1.01B
+33.5% YoY
|
1.30B
1.30B – 1.30B
+28.8% YoY
|
1.49B
1.49B – 1.49B
+14.5% YoY
|
| EBITDA |
-105.12M
est: -23.58M (-345.8%)
|
-38.39M
est: -40.30M (+4.8%)
|
-103.06M
est: -63.94M (-61.2%)
|
71.76M
est: -109.97M (+165.3%)
|
-146.82M
-146.82M – -146.82M
-33.5% YoY
|
-189.06M
-189.06M – -189.06M
-28.8% YoY
|
-216.45M
-216.45M – -216.45M
-14.5% YoY
|
| EBIT |
-138.38M
est: -53.91M (-156.7%)
|
-80.32M
est: -92.14M (+12.8%)
|
-150.51M
est: -109.96M (-36.9%)
|
24.30M
est: -189.11M (+112.9%)
|
-252.48M
-252.48M – -252.48M
-33.5% YoY
|
-325.12M
-325.12M – -325.12M
-28.8% YoY
|
-372.21M
-372.21M – -372.21M
-14.5% YoY
|
| Net Income |
-124.09M
est: -125.73M (+1.3%)
|
-76.07M
est: -71.25M (-6.8%)
|
-141.20M
est: -63.15M (-123.6%)
|
8.08M
est: 11.84M (-31.7%)
|
55.25M
55.25M – 55.25M
+366.7% YoY
|
122.35M
122.35M – 122.35M
+121.4% YoY
|
161.82M
161.82M – 161.82M
+32.3% YoY
|
| SGA |
167.57M
est: 66.64M (+151.4%)
|
199.69M
est: 113.89M (+75.3%)
|
251.95M
est: 213.05M (+18.3%)
|
221.18M
est: 366.41M (-39.6%)
|
489.20M
489.20M – 489.20M
+33.5% YoY
|
629.94M
629.94M – 629.94M
+28.8% YoY
|
721.18M
721.18M – 721.18M
+14.5% YoY
|
| EPS |
-0.30
est: -0.30 (+0.0%)
|
-0.18
est: -0.17 (-5.9%)
|
-0.34
est: -0.16 (-112.5%)
|
-0.05
est: 0.03 (-266.7%)
|
0.14
0.14 – 0.14
+366.7% YoY
|
0.31
0.31 – 0.31
+121.4% YoY
|
0.41
0.41 – 0.41
+32.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gaohong Gu | Senior Vice President | — | male |
| Guang Rong Wang | Vice President & Director | — | female |
| Gufang Su | Deputy Director of Process R&D | — | male |
| Hong Qin | Vice President | — | male |
| Jibing Zhang | Factory Manager of Human Protein | — | male |
| Jie Zhang | Chief Executive Officer, President & Director | — | male |
| Qide Li | Director of Pharmaceutical Research Institute | — | male |
| Tie Sun | Director of Pharmacology and Toxicology and Senior Director of Biologics R&D | — | male |
| Yan Liu | Financial Director, Secretary & Accounting Supervisor | — | female |
| Yu Yuan | Quality Center Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688488.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
